Association for Molecular Pathology et al. v. Myriad Genetics, Inc., et al.
URI: https://gptkb.org/entity/Association_for_Molecular_Pathology_et_al._v._Myriad_Genetics,_Inc.,_et_al.
GPTKB entity
Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:law
|
| gptkbp:alsoKnownAs |
gptkb:AMP_v._Myriad
|
| gptkbp:arguedDate |
April 15, 2013
|
| gptkbp:citation |
gptkb:569_U.S._576
subsequent gene patent litigation |
| gptkbp:country |
gptkb:United_States
|
| gptkbp:date |
June 13, 2013
|
| gptkbp:decidedBy |
gptkb:Supreme_Court_of_the_United_States
|
| gptkbp:decision |
unanimous decision
|
| gptkbp:defendant |
gptkb:Myriad_Genetics,_Inc.
|
| gptkbp:heldBy |
complementary DNA (cDNA) is patent eligible
naturally occurring DNA sequences cannot be patented |
| https://www.w3.org/2000/01/rdf-schema#label |
Association for Molecular Pathology et al. v. Myriad Genetics, Inc., et al.
|
| gptkbp:impact |
changed gene patenting practices in the US
|
| gptkbp:opinionBy |
gptkb:Justice_Clarence_Thomas
|
| gptkbp:plaintiff |
gptkb:Association_for_Molecular_Pathology
|
| gptkbp:precededBy |
Federal Circuit decision
|
| gptkbp:relatedTo |
gptkb:BRCA1_gene
gptkb:BRCA2_gene |
| gptkbp:subject |
gptkb:US_patent
human genes |
| gptkbp:bfsParent |
gptkb:133_S._Ct._1761
|
| gptkbp:bfsLayer |
7
|